» Articles » PMID: 11607811

Mechanisms of Chromosomal Translocations in B Cell Lymphomas

Overview
Journal Oncogene
Date 2001 Oct 19
PMID 11607811
Citations 219
Authors
Affiliations
Soon will be listed here.
Abstract

Reciprocal chromosomal translocations involving the immunoglobulin (Ig) loci are a hallmark of most mature B cell lymphomas and usually result in dysregulated expression of oncogenes brought under the control of the Ig enhancers. Although the precise mechanisms involved in the development of these translocations remains essentially unknown, a clear relationship has been established with the mechanisms that lead to Ig gene remodeling, including V(D)J recombination, isotype switching and somatic hypermutation. The common denominator of these three processes in the formation of Ig-associated translocations is probably represented by the fact that each of these processes intrinsically generates double-strand DNA breaks. Since isotype switching and somatic hypermutation occur in germinal center (GC) B cells, the origin of a large number of B cell lymphomas from GC B cells is likely closely related to aberrant hypermutation and isotype switching activity in these B cells.

Citing Articles

Diffuse large B cell lymphoma (DLBCL): epidemiology, pathophysiology, risk stratification, advancement in diagnostic approaches and prospects: narrative review.

Berhan A, Almaw A, Damtie S, Solomon Y Discov Oncol. 2025; 16(1):184.

PMID: 39954204 PMC: 11829893. DOI: 10.1007/s12672-025-01958-w.


B Cell Differentiation and the Origin and Pathogenesis of Human B Cell Lymphomas.

Weniger M, Seifert M, Kuppers R Methods Mol Biol. 2024; 2865:1-30.

PMID: 39424718 DOI: 10.1007/978-1-0716-4188-0_1.


Centrioles are frequently amplified in early B cell development but dispensable for humoral immunity.

Schapfl M, LoMastro G, Braun V, Hirai M, Levine M, Kiermaier E Nat Commun. 2024; 15(1):8890.

PMID: 39406735 PMC: 11480410. DOI: 10.1038/s41467-024-53222-4.


Targeting CD38 with monoclonal antibodies disrupts key survival pathways in paediatric Burkitt's lymphoma malignant B cells.

Klasener K, Herrmann N, Haversen L, Sundell T, Sundqvist M, Lundqvist C Clin Transl Immunology. 2024; 13(10):e70011.

PMID: 39364393 PMC: 11447455. DOI: 10.1002/cti2.70011.


Imatinib mesylate reduces c-MYC expression in double-hit lymphoma cells by suppressing inducible cytidine deaminase.

Zhang J, Zhou S, Jiang S, He F, Tu Y, Hu H J Cancer Res Clin Oncol. 2024; 150(9):426.

PMID: 39299959 PMC: 11413099. DOI: 10.1007/s00432-024-05939-4.